Cost and effectiveness of autologous haematopoietic stem cell transplantation and high-efficacy disease-modifying therapies in relapsing–remitting multiple sclerosis

Alice Mariottini,Chiara Nozzoli,Ilaria Carli,Filippo Landi,Valentina Gigli,Anna Maria Repice,Alessandra Ipponi,Michele Cecchi,Riccardo Boncompagni,Riccardo Saccardi,Luca Massacesi

DOI: https://doi.org/10.1007/s10072-024-07308-y

2024-01-26

Neurological Sciences

Abstract:Abstract Background Autologous haematopoietic stem cell transplantation (AHSCT) is a highly effective one-off treatment for relapsing–remitting multiple sclerosis (RR-MS), potentially representing an optimal front-loading strategy for costs. Objective Exploring cost/effectiveness of AHSCT and high-efficacy disease-modifying treatments (HE-DMTs) in RR-MS, estimating costs at our centre in Italy, where National Health Service (NHS) provides universal health coverage. Methods Costs (including drugs, inpatient/outpatient management) for treatment with AHSCT and HE-DMTs were calculated as NHS expenditures over 2- and 5-year periods. Cost-effectiveness for each treatment was estimated as “cost needed to treat” (CNT), i.e. expense to prevent relapses, progression, or disease activity (NEDA) in one patient over n -years, retrieving outcomes from published studies. Results Costs of AHSCT and HE-DMTs were similar over 2 years, whereas AHSCT was cheaper than most HE-DMTs over 5 years (€46 600 vs €93 800, respectively). When estimating cost-effectiveness of treatments, over 2 years, mean CNT of HE-DMTs for NEDA was twofold that of AHSCT, whereas it was similar for relapses and disability. Differences in CNT were remarkable over 5 years, especially for NEDA, being mean CNT of HE-DMTs €382 800 vs €74 900 for AHSCT. Conclusions AHSCT may be highly cost-effective in selected aggressive RR-MS. Besides priceless benefits for treated individuals, cost-savings generated by AHSCT may contribute to improving healthcare assistance at a population level.

neurosciences,clinical neurology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to evaluate the cost - effectiveness of autologous hematopoietic stem cell transplantation (AHSCT) and high - efficacy disease - modifying treatments (HE - DMTs) in relapsing - remitting multiple sclerosis (RR - MS). Specifically, the study aims to:

1. **Estimate costs**: Calculate the total costs of AHSCT and HE - DMTs for RR - MS patients within 2 and 5 years in the Italian National Health Service (NHS), including costs of drugs, inpatient/outpatient management, etc.
2. **Evaluate cost - effectiveness**: Evaluate the cost - effectiveness of different treatment methods through the "cost per treatment required" (CNT) indicator, that is, the cost required to prevent relapse, progression or no evidence of disease activity (NEDA) per patient within n years.

### Research background
- **AHSCT**: Autologous hematopoietic stem cell transplantation is a highly effective single - treatment regimen and may become the optimal upfront strategy for RR - MS, which helps to reduce long - term medical costs.
- **HE - DMTs**: High - efficacy disease - modifying treatments usually require long - term use and generate high costs every year.

### Research methods
- **Cost estimation**: Include costs of drugs, inpatient/outpatient management, laboratory tests, etc.
- **Time frame**: Consider treatment cycles of 2 and 5 years respectively.
- **CNT calculation**: Based on published research results, calculate the costs required for each treatment method to achieve specific treatment effects within 2 and 5 years.

### Main findings
- **2 - year cost**: The costs of AHSCT and HE - DMTs are similar, but AHSCT is more cost - effective in maintaining the NEDA state.
- **5 - year cost**: The cost of AHSCT is significantly lower than most HE - DMTs (€46,600 vs €93,800). In particular, in terms of maintaining the NEDA state, the CNT of HE - DMTs is five times that of AHSCT (€382,800 vs €74,900).

### Conclusions
- **Cost - effectiveness**: AHSCT is highly cost - effective in selected highly active RR - MS patients, especially in long - term treatment.
- **Economic savings**: AHSCT not only has great benefits for individual patients, but also can improve the medical service level of the whole society by saving medical costs, especially in low - income countries where the current access to HE - DMTs is limited.

### Formula examples
- **CNT calculation formula**:
\[
\text{CNT}=\text{Number of patients requiring treatment}\times\text{Treatment cost}
\]
For example, if the MS - activity - free survival rate within 2 years is 20% and the 2 - year treatment cost is €20,000, then:
\[
\text{CNT}=5\times20,000 = 100,000
\]

Through these analyses, the study provides important insights into the cost - effectiveness of AHSCT and HE - DMTs in the treatment of RR - MS, which helps to optimize the allocation of medical resources.